Skip to main content
All lobbying filings

THE MCMANUS GROUP

Lobbying for ZIMMER BIOMET · A global leader in musculoskeletal healthcare.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$50,000
What the client paid this registrant for the period.
Client based in
Indiana

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Access and reimbursement of medical devices in Medicare program. Issues related to capping beneficiary copayments for Medicare beneficiaries in ambulatory surgery centers, included in Medicare Beneficiary Co-Pay Fairness Act of 2025(H.R. 3006/S. 1776) The Ensuring Patient Access to Critical Breakthrough Products Act (H.R. 5343/S. 1717)

Issues related to Artificial Intelligences approval in Medical Devices. Issues related to The SECURE Data Act (H.R. 8413).

 Bills named in this filing 5
  • H.R. 3006
    To amend title XVIII of the Social Security Act to limit the coinsurance amount for certain services furnished in an am…
  • S. 1776
    Medicare Beneficiary Co-Pay Fairness Act
  • H.R. 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S. 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
  • H.R. 8413
    SECURE Data Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem